Ipsen

* ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. ipsen also has a significant presence in primary care. the group has an active policy of partnerships. ipsen's r&d is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (les ulis, fr ; slough/oxford, uk ; cambridge, us). in 2014, r&d expenditure totaled close to €187 million (about 15% of group sales). the group has more than 4,500 employees. *ipsen est un groupe mondial biotechnologique de s